New development of epigenome drug discovery to realize oncogene selectivity

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K15592
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: General surgery
• Research Institution: Osaka University
• Principal Investigator: SATOH Taroh 大阪大学, 医学系研究科, 寄附講座教授 (40368303)
• Co-Investigator(Kenkyū-buntansha): 西田 尚弘 大阪大学, 医学系研究科, 助教 (50588118) ; 今野 雅允 大阪大学, 医学系研究科, 寄附講座講師 (80618207) ; 川本 弘一 大阪大学, 医学部附属病院, その他 (30432470) ; 小関 準 大阪大学, 医学系研究科, 特任助教(常勤) (20616669) ; 工藤 敏啓 大阪大学, 医学系研究科, 寄附講座助教 (20593859) ; 坂井 大介 大阪大学, 医学系研究科, 寄附講座助教 (10621071)
• Co-Investigator(Renkei-kenkyūsha): ISHII Hideshi 大阪大学, 大学院医学系研究科, 特任教授 (10280736) ; MORI Masaki 大阪大学, 大学院医学系研究科, 教授 (70190999)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: 癌 / 酵素

Outline of Final Research Achievements

To target an oncogene in clinical setting, it is important to develop effective drug discovery based on the accurate information in epigenome. In the present study, the histone demethylating enzyme controlled by oncogene c - MYC was identified as a target candidate by using the comprehensive transcriptome analysis method. As a result, it was shown that histone methylation modification system was important and that NO66 played an important role in gastrointestinal cancer as its target. Furthermore we showed that it was possible to overcome refractory cancer by drug discovery targeting MYC - NO 66, for which we constructed the foundation.

Free Research Field

腫瘍内科学